Alembic Pharma gets USFDA nod for generic hypertension treatment capsules

Alembic Pharmaceuticals has received USFDA final approval for its generic Diltiazem Hydrochloride extended-release capsules in strengths of 120 mg, 180 mg, and 240 mg to treat hypertension and chronic stable angina. These capsules are therapeutically equivalent to Allergan Sales LLC’s Dilacor XR, with an estimated market size of USD 28.2 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LRUItQN
via IFTTT